Form 4 for INDP Indaptus Therapeutics, Inc.
Accepted 2025-07-29 00:00:00 ET · period of report 2025-07-27 · accession 0001641172-25-021376 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-07-29 | 2025-07-27 | INDP | Meckler Jeffrey A | CEO, Dir | A - Grant | $8.30 | +6,068 | 13.3K | +84% | +$50.4K |
| D | 2025-07-29 | 2025-07-27 | INDP | Meckler Jeffrey A | CEO, Dir | A - Grant | $8.30 | +12.1K | 16.7K | +267% | +$100.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-27 | A | A | 6,068 | $8.30 | 13,312 | D | — | — | (F1) The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025. |
| 2 | Derivative | Common Stock Warrants | 2025-07-27 | A | A | 12,136 | $8.30 | 16,688 | D | $8.30 · 2025-07-27 to 2030-07-27 | 12,136 Common Stock | (F1) The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025. |